Identification
- Summary
Betamethasone is a systemic corticosteroid used to relieve inflammation in various conditions, including but not limited to allergic states, dermatologic disorders, gastrointestinal diseases, and hematological disorders.
- Brand Names
- Betaderm, Betaloan Suik, Beteflam, Celestoderm, Celestone Soluspan, Dermacinrx Therazole Pak, Diprolene, Diprosalic, Diprosone, Dovobet, Enstilar, Fucibet, Lotriderm, Lotrisone, Luxiq, Marbeta, Rivasone, Rolene, Rosone, Sernivo, Taclonex, Valisone-G, Wynzora
- Generic Name
- Betamethasone
- DrugBank Accession Number
- DB00443
- Background
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.11 It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.11 Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.11
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Betamethasone (DB00443)
- Weight
- Average: 392.4611
Monoisotopic: 392.199902243 - Chemical Formula
- C22H29FO5
- Synonyms
- 16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
- 9-Fluoro-16β-methylprednisolone
- 9α-Fluoro-16β-methylprednisolone
- beta-Methasone alcohol
- Betadexamethasone
- Betametasona
- Betamethasone
- Bétaméthasone
- Betamethasonum
- External IDs
- NSC-39470
- SCH 4831
- SCH-4831
Pharmacology
- Indication
As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.12,14,15 Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.16 The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.13
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Acquired hemolytic anemia •••••••••••• ••••••••• Adjunct therapy in treatment of Acute gouty arthritis •••••••••••• ••••••••• Management of Adrenocortical insufficiency •••••••••••• ••••••••• Management of Alopecia areata •••••••••••• ••••••••• Adjunct therapy in treatment of Ankylosing spondylitis •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Corticosteroids bind to the glucocorticoid receptor inhibiting pro-inflammatory signals, while promoting anti-inflammatory signals.1 Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.1 Patients who require long-term treatment with a corticosteroid should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.1
- Mechanism of action
Glucocorticoids inhibit neutrophil apoptosis and demargination, and inhibit NF-Kappa B and other inflammatory transcription factors.1 They also inhibit phospholipase A2, leading to decreased formation of arachidonic acid derivatives.1 In addition, glucocorticoids promote anti-inflammatory genes like interleukin-10.1
Corticosteroids like betamethasone can act through nongenomic and genomic pathways.3 The genomic pathway is slower and occurs when glucocorticoids activate glucocorticoid receptors and initiate downstream effects that promote transcription of anti-inflammatory genes including phosphoenolpyruvate carboxykinase (PEPCK), IL-1-receptor antagonist, and tyrosine amino transferase (TAT).3 On the other hand, the nongenomic pathway is able to elicit a quicker response by modulating T-cell, platelet and monocyte activity through the use of existing membrane-bound receptors and second messengers.3
Target Actions Organism AGlucocorticoid receptor agonistHumans - Absorption
The absorption and potency of any topical corticosteroid including betamethasone depends on the vehicle in which the steroid is delivered. For example, betamethasone dipropionate 0.05% ointment is classified as a highly potent topical steroid, while betamethasone dipropionate 0.05% cream or lotion is considered to be moderately potent.4
There are several structural modifications that can determine the potency of a topical corticosteroid. For example, corticosteroids containing a halogen at specific carbons, or that contain esters are more potent due to enhanced lipophilicity.5 As such, there is a marked difference between topical products containing betamethasone dipropionate vs. betamethasone valerate. Betamethasone dipropionate contains 2 esters which enhances its potency, while betamethasone valerate has only one ester and is less potent.5
It should be noted that the use of occlusive dressings with topical steroids significantly increases the absorption, increasing the risk for adverse effects.14
- Volume of distribution
In a study that included Indian women of reproductive age, the volume of distribution following a single intramuscular dose of betamethasone phosphate was 94,584±23,539 mL(s).9
- Protein binding
Betamethasone valerate binds to serum albumin and corticosteroid-binding globulin.7,8
- Metabolism
The metabolism of betamethasone yields 6 metabolites.10 The metabolic processes include 6β hydroxylation, 11β-hydroxyl oxidation, and reduction of the C-20 carbonyl group followed by removal of the side chain.10
- Route of elimination
Corticosteroids are eliminated predominantly in the urine.2
- Half-life
In a study that included Indian women of reproductive age, the half-life following a single intramuscular dose of betamethasone phosphate was 10.2 ± 2.5 hours.9
- Clearance
In a study that included Indian women of reproductive age, the CL/F following a single intramuscular dose of betamethasone phosphate was 6,466 ± 805 mL/hour.9
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Chronic high doses of glucocorticoids can lead to the development of cataracts, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.6 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.6
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Betamethasone can be increased when it is combined with Abametapir. Abatacept The risk or severity of adverse effects can be increased when Betamethasone is combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be increased when combined with Betamethasone. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Betamethasone. Acarbose The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Acarbose. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Betamethasone acetate TI05AO53L7 987-24-6 AKUJBENLRBOFTD-QZIXMDIESA-N Betamethasone benzoate 877K0XW47A 22298-29-9 SOQJPQZCPBDOMF-YCUXZELOSA-N Betamethasone dipropionate 826Y60901U 5593-20-4 CIWBQSYVNNPZIQ-XYWKZLDCSA-N Betamethasone sodium phosphate 7BK02SCL3W 151-73-5 PLCQGRYPOISRTQ-LWCNAHDDSA-L Betamethasone valerate 9IFA5XM7R2 2152-44-5 SNHRLVCMMWUAJD-SUYDQAKGSA-N - International/Other Brands
- Bentelan (Defiante) / Betnovate (GlaxoSmithKline) / Celestamine (Schering-Plough) / Diprosone (Schering-Plough) / Procort / Rinderon (Shionogi Seiyaku)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Beben Gel 0.025% Gel 0.025 % Topical Parke Davis Division, Warner Lambert Canada Inc. 1973-12-31 1999-04-08 Canada 
Betacort Scalp Lotion 0.1% Liquid .1 % Topical Icn Pharmaceuticals 1981-12-31 2005-04-26 Canada Betaderm Crm 0.05% Cream 0.05 % Topical Taro Pharmaceuticals, Inc. 1979-12-31 Not applicable Canada Betaderm Crm 0.1% Cream 0.1 % Topical Taro Pharmaceuticals, Inc. 1979-12-31 Not applicable Canada Betaderm Lotion 0.1% Lotion 0.1 % Topical Taro Pharmaceuticals, Inc. 1979-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Betamethasone Cream 0.5 mg/1g Topical Impax Generics 2004-01-23 2017-06-30 US 
Betamethasone Dipropionate Ointment 0.5 mg/1g Topical Prasco Laboratories 2021-06-01 Not applicable US Betamethasone Dipropionate Cream 0.5 mg/1g Topical Golden State Medical Supply, Inc. 1992-04-30 Not applicable US Betamethasone Dipropionate Cream 0.5 mg/1g Topical Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc 2012-03-26 Not applicable US Betamethasone Dipropionate Cream 0.5 mg/1g Topical A-S Medication Solutions 2006-09-28 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ซาโนเบท ครีม Cream 0.1 %w/w บริษัท โอสถ อินเตอร์ แลบบอราทอรีส์ จำกัด จำกัด 2007-03-26 Not applicable Thailand 
เบต้าเนท Cream 0.05 %w/w ห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม 1997-06-05 Not applicable Thailand - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Amolg A Betamethasone valerate (0.61 mg/1g) + Gentamicin sulfate (1 mg/1g) Cream Topical OASIS TRADING 2018-11-15 Not applicable US ANTASONE CREAM Betamethasone (1 mg/g) + Gentamicin (1 mg) Cream Topical ZYFAS PHARMA PTE LTD 1988-06-25 Not applicable Singapore 
B-MYCIN CREAM Betamethasone (0.5 mg/g) + Gentamicin (1 mg/g) Cream Topical YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD 2013-07-25 Not applicable Singapore B-TASONE-G CREAM Betamethasone (0.1 % w/w) + Gentamicin (0.3 % w/w) Cream Topical BEACONS PHARMACEUTICALS PTE. LTD. 1990-02-26 Not applicable Singapore BEBEN CLOROSSINA Betamethasone benzoate (0.1 %) + Chloroxine (0.5 %) Ointment Topical Teofarma S.R.L. 2014-07-08 2021-07-21 Italy 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Amolg A Betamethasone valerate (0.61 mg/1g) + Gentamicin sulfate (1 mg/1g) Cream Topical OASIS TRADING 2018-11-15 Not applicable US Betalido Kit Betamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL) + Isopropyl alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL) Kit Infiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical Advanced Rx Pharmacy of Tennessee, LLC 2023-05-10 Not applicable US Betalido Kit Betamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL) + Isopropyl alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL) Kit Infiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical Asclemed Usa, Inc. 2014-06-13 Not applicable US Betalido Kit Betamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL) + Isopropyl alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL) Kit Infiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical Advanced Rx Pharmacy of Tennessee, LLC 2023-05-10 Not applicable US Betalido Kit Betamethasone sodium phosphate (3 mg/1mL) + Betamethasone acetate (3 mg/1mL) + Isopropyl alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL) Kit Infiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical Asclemed Usa, Inc. 2014-06-13 Not applicable US
Categories
- ATC Codes
- R01AD06 — Betamethasone
- R01AD — Corticosteroids
- R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
- R01 — NASAL PREPARATIONS
- R — RESPIRATORY SYSTEM
- D07BC — Corticosteroids, potent, combinations with antiseptics
- D07B — CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- S01BA — Corticosteroids, plain
- S01B — ANTIINFLAMMATORY AGENTS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- S01BB — Corticosteroids and mydriatics in combination
- S01B — ANTIINFLAMMATORY AGENTS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- S01CB — Corticosteroids/antiinfectives/mydriatics in combination
- S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- H02AB — Glucocorticoids
- H02A — CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
- H02 — CORTICOSTEROIDS FOR SYSTEMIC USE
- H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
- C05AA — Corticosteroids
- C05A — AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
- C05 — VASOPROTECTIVES
- C — CARDIOVASCULAR SYSTEM
- S03CA — Corticosteroids and antiinfectives in combination
- S03C — CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
- S03 — OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
- S — SENSORY ORGANS
- D07XC — Corticosteroids, potent, other combinations
- D07X — CORTICOSTEROIDS, OTHER COMBINATIONS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- D07AC — Corticosteroids, potent (group III)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- A07EA — Corticosteroids acting locally
- A07E — INTESTINAL ANTIINFLAMMATORY AGENTS
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- R03BA — Glucocorticoids
- R03B — OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- S03BA — Corticosteroids
- S03B — CORTICOSTEROIDS
- S03 — OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
- S — SENSORY ORGANS
- S01CA — Corticosteroids and antiinfectives in combination
- S01C — ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- Drug Categories
- Adrenal Cortex Hormones
- Adrenals
- Agents Causing Muscle Toxicity
- Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
- Alimentary Tract and Metabolism
- Anti-Inflammatory Agents
- Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
- Corticosteroid Hormone Receptor Agonists
- Corticosteroids
- Corticosteroids Acting Locally
- Corticosteroids for Systemic Use
- Corticosteroids for Systemic Use, Plain
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Potent (Group III)
- Cytochrome P-450 CYP2A6 Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2B6 Inducers (strength unknown)
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C19 Inducers (strength unknown)
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C8 Inducers (strength unknown)
- Cytochrome P-450 CYP2C9 Inducers
- Cytochrome P-450 CYP2C9 Inducers (strength unknown)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Inducers
- Cytochrome P-450 CYP3A5 Inducers (weak)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Substrates
- Dermatologicals
- Drugs for Obstructive Airway Diseases
- Fused-Ring Compounds
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hyperglycemia-Associated Agents
- Immunosuppressive Agents
- Intestinal Antiinflammatory Agents
- Nasal Preparations
- Ophthalmological and Otological Preparations
- Ophthalmologicals
- Otologicals
- P-glycoprotein substrates
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Respiratory System Agents
- Steroids
- Steroids, Fluorinated
- Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
- Thyroxine-binding globulin inhibitors
- Vasoprotectives
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols show 8 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 20-oxosteroid / 21-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Alcohol / Aliphatic homopolycyclic compound show 23 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:3077)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 9842X06Q6M
- CAS number
- 378-44-9
- InChI Key
- UREBDLICKHMUKA-DVTGEIKXSA-N
- InChI
- InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
- IUPAC Name
- (1R,2S,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
- SMILES
- [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- Synthesis Reference
Fernando AHUMADA AYALA, "SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE." U.S. Patent US20100063015, issued March 11, 2010.
US20100063015- General References
- Yasir M, Sonthalia S: Corticosteroid Adverse Effects . [Article]
- Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. [Article]
- Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P: Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. Epub 2012 Nov 5. [Article]
- Spada F, Barnes TM, Greive KA: Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas J Dermatol. 2018 Aug;59(3):e168-e174. doi: 10.1111/ajd.12762. Epub 2018 Feb 7. [Article]
- Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S: Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):371-8. doi: 10.4103/0378-6323.178903. [Article]
- Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. doi: 10.4103/0976-500X.120975. [Article]
- Pontremoli C, Barbero N, Viscardi G, Visentin S: Insight into the interaction of inhaled corticosteroids with human serum albumin: A spectroscopic-based study. J Pharm Anal. 2018 Feb;8(1):37-44. doi: 10.1016/j.jpha.2017.07.003. Epub 2017 Jul 5. [Article]
- Simard M, Underhill C, Hammond GL: Functional implications of corticosteroid-binding globulin N-glycosylation. J Mol Endocrinol. 2018 Feb;60(2):71-84. doi: 10.1530/JME-17-0234. Epub 2017 Dec 22. [Article]
- Jobe AH, Milad MA, Peppard T, Jusko WJ: Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India. Clin Transl Sci. 2020 Mar;13(2):391-399. doi: 10.1111/cts.12724. Epub 2019 Dec 13. [Article]
- Butler J, Gray CH: The metabolism of betamethasone. J Endocrinol. 1970 Mar;46(3):379-90. doi: 10.1677/joe.0.0460379. [Article]
- Authors unspecified: Corticosteroids . [Article]
- FDA Approved Drug Products: Diprosone (Betamethasone dipropionate) ointment [Link]
- FDA Approved Drug Products: Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate) injectable suspension [Link]
- DIPROLENE® (augmented betamethasone dipropionate) ointment, for topical use - FDA Label [Link]
- FDA Approved Drug Products: Luxiq (betamethasone valerate) Foam [Link]
- FDA Approved Drug Products: Enstilar (calcipotriene and betamethasone dipropionate) foam [Link]
- Celestone Soluspan Product Insert (Injectable) [File]
- External Links
- Human Metabolome Database
- HMDB0014586
- KEGG Drug
- D00244
- PubChem Compound
- 9782
- PubChem Substance
- 46505155
- ChemSpider
- 9399
- BindingDB
- 73823
- 1514
- ChEBI
- 3077
- ChEMBL
- CHEMBL632
- ZINC
- ZINC000003876136
- Therapeutic Targets Database
- DAP001043
- PharmGKB
- PA164754818
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Betamethasone
- FDA label
- Download (37.5 KB)
- MSDS
- Download (71.9 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Basic Science Psoriasis / Psoriasis Vulgaris (Plaque Psoriasis) / Skin and Connective Tissue Diseases / Skin Diseases / Skin Diseases, Papulosquamous 1 4 Active Not Recruiting Treatment DeQuervain's Tendinopathy 1 4 Active Not Recruiting Treatment Osteoarthritis of the Knee 1 4 Completed Other Psoriasis Vulgaris (Plaque Psoriasis) 1 4 Completed Prevention Hand Eczema 1
Pharmacoeconomics
- Manufacturers
- Schering corp sub schering plough corp
- Parke davis div warner lambert co
- Parke davis pharmaceutical research div warner lambert co
- Altana inc
- Glenmark generics inc usa
- Perrigo new york inc
- Taro pharmaceuticals usa inc
- Tolmar inc
- Schering corp
- Savage laboratories inc div altana inc
- Actavis mid atlantic llc
- E fougera div altana inc
- Pharmaderm div altana inc
- Teva pharmaceuticals usa inc
- Alpharma us pharmaceuticals division
- Taro pharmaceuticals inc
- Teva pharmaceuticals usa
- Watson laboratories inc
- Connectics corp
- Tj roaco ltd
- Pharmafair inc
- Stat trade inc
- Packagers
- Accra Pac Inc.
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- American Regent
- A-S Medication Solutions LLC
- C.O. Truxton Inc.
- Clint Pharmaceutical Inc.
- Contract Pharm
- Crown Laboratories Inc.
- Darby Dental Supply Co. Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- DPT Laboratories Ltd.
- E. Fougera and Co.
- Faithful Friends Homeopathic Inc.
- Genesis Pharmaceutical Inc.
- Glenmark Generics Ltd.
- Hikma Pharmaceuticals
- Major Pharmaceuticals
- Martin Surgical Supply
- Mason Distributors
- Medisca Inc.
- Merit Pharmaceuticals
- Nycomed Inc.
- Palmetto Pharmaceuticals Inc.
- Patheon Inc.
- Perrigo Co.
- Pharmaforce Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Qualitest
- Quality Care
- Rebel Distributors Corp.
- SAL Pharma
- Sandoz
- Savage Labs
- Schering Corp.
- Stat Rx Usa
- Stiefel Labs
- Taro Pharmaceuticals USA
- Teva Pharmaceutical Industries Ltd.
- Tolmar Inc.
- Warrick Pharmaceuticals Corp.
- Dosage Forms
Form Route Strength Ointment Ophthalmic Capsule Oral Solution / drops Auricular (otic); Ophthalmic Syrup Oral Tablet Gel Topical Gel Topical 0.1 % Gel Topical 0.025 % Ointment Ophthalmic 3 g Spray Nasal 50 mcg/1dose Tablet Oral Tablet Cream Ointment Topical 0.12 % w/w Capsule Oral 1 MG Capsule Oral 2 MG Injection Intramuscular; Intravenous 4 mg/2ml Injection, solution Intramuscular; Intravenous 1.5 MG/2ML Injection, solution Intramuscular; Intravenous 4 MG/2ML Solution Topical 0.05 %w/v Lotion Topical 0.064 % w/v Ointment Topical 0.05 % w/w Ointment Cream Topical 0.064 % W/W Ointment Topical 0.064 % W/W Capsule Capsule Nasal Emulsion Topical Kit Infiltration Gel Conjunctival Ointment Conjunctival Solution / drops Conjunctival Suspension / drops Conjunctival Suspension / drops Conjunctival 0.5 % Liquid Topical .1 % Ointment Solution Oral 1 mg/g Gel Topical .1 % Cream Solution / drops Ophthalmic Suspension Intra-articular; Intralesional; Intramuscular Kit Infiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical Cream Cutaneous Cream Topical 0.05 g Cream Topical 0.064 g Suspension Intra-articular; Intralesional; Intramuscular 5 mg Solution Intramuscular; Intravenous 8 mg Solution Intramuscular; Intravenous 4 mg Ointment Topical 61.728 mg Ointment Topical 0.05 g Cream Topical 100 mg Solution Topical Injection, solution Parenteral 1.5 MG/2ML Injection, solution Parenteral 4 MG/2ML Tablet Oral 1 MG Injection, solution Parenteral 4 MG/1ML Injection, suspension Epidural; Intramuscular; Intraspinal; Intrathecal Injection, suspension Intramuscular Cream Topical 0.12 % w/w Cream Topical .64 mg/1g Cream Topical 0.5 mg/1g Cream Topical 0.64 mg/1g Cream, augmented Topical 0.5 mg/1g Gel Topical .50 mg/1g Gel Topical 0.5 mg/1g Gel Topical 0.64 mg/1g Lotion Topical 0.5 mg/1mL Lotion, augmented Topical 0.5 mg/1mL Ointment Topical 0.05 mg/1g Ointment Topical 0.5 mg/1g Ointment, augmented Topical 0.5 mg/1g Solution Topical Lotion Topical 0.64 mg/1mL Ointment Topical 0.025 % w/w Ointment Topical 0.05 % w/w Injection, solution Epidural; Intramuscular; Intraspinal; Intrathecal 12 mg/1mL Cream Topical 0.1 % Cream Topical 1 mg/1g Cream Topical 1.2 mg/1g Lotion Cutaneous 1 mg/1mL Lotion Topical 1 mg/1mL Ointment Topical 1 mg/1g Ointment Topical 1.2 mg/1g Lotion Topical 1.22 mg / g Cream Topical 0.1 g Cream Topical .64 mg / g Lotion Topical .64 mg / g Ointment Topical .64 mg / g Solution Intra-articular; Intralesional; Intramuscular; Intravenous 8 mg Patch Topical 0.1 % w/w Plaster 2250 mg Solution Intravenous 8.00 mg Solution / drops; suspension / drops Nasal 1 mg/ml Solution / drops Auricular (otic); Ophthalmic .1 % Liquid Auricular (otic); Ophthalmic 0.1 % Tablet Topical 0.1 mg Enema Rectal 5 mg / 100 mL Tablet Oral .5 mg / tab Tablet, effervescent Oral 0.5 mg / evt Cream Topical 1 mg/g Solution Topical 1 mg/g Ointment Topical 1 mg/g Cream Topical .05 % Cream Topical .1 % Lotion Topical 0.1 g Suspension Cutaneous 0.094 g Lotion 20 ml Lotion Topical .1 % Ointment Topical .1 % Lotion 0.1 % Solution Topical 0.1 % w/w Aerosol, foam Cutaneous 0.1 % Ointment Cutaneous Spray Nasal Spray, suspension Nasal Injection Intradermal; Intramuscular 5 mg/ml Injection Intra-arterial; Intradermal; Intralesional; Intramuscular Injection Intra-articular; Intralesional; Intramuscular Solution Parenteral 5.265 mg Injection, suspension Parenteral Lotion Topical Ointment Topical 0.1 % Spray Topical Ointment Topical 0.05 % Injection, solution Solution Oral 0.6 mg/5mL Solution Parenteral 4.000 mg Solution / drops Oral Tablet, coated Injection Intralesional; Intramuscular 3 mg/ml Solution Oral 0.050 g Tablet, extended release Oral 1 mg Injection, suspension Intra-articular; Intralesional; Intramuscular; Soft tissue Suspension Intra-articular; Intrabursal; Intradermal; Intramuscular Syrup Oral 12 mg Tablet Oral 2 mg Cream; kit; solution Topical Cream Topical Patch Topical Patch Topical 2250 MG Suspension Intramuscular 2.00 mg Gel Ointment Topical 0.5 mg/g Aerosol, foam Topical 1 mg/g Insert Vaginal Kit Topical Ointment Topical 0.1 % w/w Lotion Topical 0.1 % w/v Injection Intramuscular Ointment Topical 0.5 mg/g Lotion Topical 0.5 mg/1g Injection Ointment 0.05 % Solution Cutaneous Ointment 0.5 mg/g Cream Cutaneous 0.064 g Cream Ophthalmic Cream Topical 0.05 % w/w Lotion Topical 0.05 % w/w Ointment Cutaneous 0.064 g Solution Oral 0.5 mg/g Solution Topical 0.05 % Ointment Topical 0.05 %w/w Cream Topical 0.05 % Injection Intra-articular; Intrabursal; Intralesional; Periarticular 5 mg/ml Injection Intradermal; Intralesional Suspension Parenteral Liquid Auricular (otic); Ophthalmic Cream Topical 0.05 g/100g Ointment Topical 0.05 g/100g Cream 1 MG/G Emulsion Topical 1 MG/G Ointment 1 MG/G Ointment 5 G Solution Topical 0.5 MG/G Aerosol, foam Cutaneous 5.000 mg Aerosol, foam Topical Aerosol, foam Cutaneous; Topical 0.5 mg/g Aerosol, foam Cutaneous Ointment Cutaneous Solution Parenteral 8.00 mg Tablet, effervescent Oral 0.5 MG Tablet, effervescent Oral 1 MG Solution Oral Solution Intramuscular 5.30 mg Cream Topical 0.05 % w/w Cream Cutaneous Solution Auricular (otic); Ophthalmic Solution Parenteral 5.30 mg Injection, solution; injection, suspension; kit Infiltration; Intra-articular; Intralesional; Intramuscular; Perineural; Topical Cream Topical 100 mg/100g Syrup Oral 0.01 g Cream Topical Solution Intravenous 5.260 mg Lotion Topical Aerosol, foam Topical 0.12 % Aerosol, foam Topical 1.2 mg/1g Kit Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Topical Cream Topical 0.1 % w/w Suspension Parenteral 5 mg Cream Topical 1 MG Gel Cutaneous Cream Topical 0.1 % w/w Cream Topical 0.5 mg/g Cream Topical 15 g Cream Topical 30 g Cream Topical 5 g Lotion Auricular (otic); Ophthalmic 20 ml Ointment Auricular (otic); Ophthalmic 15 g Ointment Auricular (otic); Ophthalmic 30 g Ointment Auricular (otic); Ophthalmic 5 g Tablet, film coated Lotion Topical .05 % Solution Auricular (otic) Solution / drops Auricular (otic) Solution Parenteral 5.300 mg Suspension Intramuscular Suspension Parenteral 5.000 mg Cream Topical 0.5 MG/G Kit Intra-articular; Intralesional; Intramuscular Injection, suspension Intra-articular; Intralesional; Intramuscular Cream Topical 0.5 mg / g Lotion Topical .5 mg / g Ointment Topical .5 mg / g Cream Topical .5 mg / g Ointment Topical .05 % Solution Intravenous 4.000 mg Cream Topical 0.64 mg/g Spray Topical 0.5 mg/1g Solution Oral 0.1 % Emulsion Topical 0.1 % Ointment 0.1 % Injection, solution Parenteral 4 mg/ml Cream Cutaneous 0.100 g Syrup Oral 0.5 mg/5ml Tablet Oral 0.5 mg Ointment Topical Spray, metered Topical Suspension Topical Tablet Oral Gel Topical 0.05 % Lotion Topical 0.05 % Lotion Topical 0.1 % Cream Topical 40 mg Cream Topical 0.025 % w/w Lotion Topical 0.1 % w/w Solution / drops Ophthalmic Gel Topical Ointment Topical Injection Intradermal; Intralesional; Intramuscular Cream 0.2 %w/w Tablet, film coated 0.5 mg Cream 0.1 %w/w Emulsion Topical Tablet 0.6 mg Cream 0.05 %w/w Ointment 0.05 %w/w Suspension - Prices
Unit description Cost Unit Luxiq 0.12% Foam 100 gm Can 325.17USD can Luxiq 0.12% Foam 50 gm Can 174.7USD can Diprolene 0.05% Lotion 60ml Bottle 148.19USD bottle Diprolene 0.05% Ointment 50 gm Tube 147.41USD tube Diprolene AF 0.05% Cream 50 gm Tube 147.02USD tube Betamethasone Dipropionate Aug 0.05% Ointment 45 gm Tube 118.42USD tube Diprolene 0.05% Gel 50 gm Tube 103.99USD tube Betamethasone Dipropionate Aug 0.05% Lotion 60ml Bottle 100.64USD bottle Betamethasone Dipropionate Aug 0.05% Cream 50 gm Tube 88.66USD tube Betamethasone Dipropionate Aug 0.05% Gel 50 gm Tube 88.26USD tube Diprolene 0.05% Lotion 30ml Bottle 78.79USD bottle Betamethasone acetate powd 78.03USD g Diprolene 0.05% Ointment 15 gm Tube 69.38USD tube Diprolene AF 0.05% Cream 15 gm Tube 69.38USD tube Betamethasone Dipropionate Aug 0.05% Ointment 15 gm Tube 58.83USD tube Betamethasone sod phos powder 56.61USD g Diprolene 0.05% Gel 15 gm Tube 49.99USD tube Betamethasone dp powder 48.96USD g Betamethasone valerate powd 47.89USD g Maxivate 0.05% Cream 45 gm Tube 44.99USD tube Betamethasone Dipropionate 0.05% Lotion 60ml Bottle 40.4USD bottle Betamethasone Dipropionate Aug 0.05% Cream 15 gm Tube 39.62USD tube Betamethasone Dipropionate Aug 0.05% Gel 15 gm Tube 39.46USD tube Betamethasone Dipropionate 0.05% Ointment 45 gm Tube 19.67USD tube Betamethasone Dipropionate 0.05% Cream 45 gm Tube 18.9USD tube Betamethasone Valerate 0.1% Lotion 60ml Bottle 16.99USD bottle Betamethasone Valerate 0.1% Ointment 45 gm Tube 15.87USD tube Beta-Val 0.1% Lotion 60ml Bottle 14.99USD bottle Betamethasone Dipropionate 0.05% Ointment 15 gm Tube 13.51USD tube Betamethasone Dipropionate 0.05% Cream 15 gm Tube 12.99USD tube Betamethasone Valerate 0.1% Cream 45 gm Tube 12.99USD tube Beta-Val 0.1% Cream 45 gm Tube 12.99USD tube Betamethasone Valerate 0.1% Cream 15 gm Tube 11.99USD tube Betamethasone Valerate 0.1% Ointment 15 gm Tube 11.99USD tube Beta-Val 0.1% Cream 15 gm Tube 11.99USD tube Betnesol (5 mg/100Ml) 5 mg/enm Enema 9.51USD enema Celestone soluspan 6 mg/ml 8.08USD ml Betamethasone ac-sp 6 mg/ml vial 7.68USD ml Luxiq 0.12% foam 5.01USD g Diprolene af 0.05% cream 4.19USD g Lotrisone 1-0.05% Lotion 2.89USD ml Lotrisone cream 2.71USD g Betamethasone dp aug 0.05% crm 2.17USD g Diprolene Glycol 0.05 % Glycol Cream 0.54USD g Diprolene Glycol 0.05 % Glycol Ointment 0.54USD g Ratio-Topilene 0.05 % Glycol Cream 0.54USD g Ratio-Topilene 0.05 % Glycol Ointment 0.54USD g Diprolene Glycol 0.05 % Glycol Lotion 0.49USD g Ratio-Topilene 0.05 % Glycol Lotion 0.49USD g Prevex B 0.1 % Occlusive Cream 0.4USD g Beta-val 0.1% cream 0.32USD g Ratio-Ectosone Regular 0.1 % Lotion 0.3USD g Ratio-Ectosone Mild 0.05 % Lotion 0.23USD g Diprosone 0.05 % Ointment 0.23USD g Ratio-Topisone 0.05 % Ointment 0.23USD g Diprosone 0.05 % Cream 0.21USD g Diprosone 0.05 % Lotion 0.21USD g Ratio-Topisone 0.05 % Cream 0.21USD g Ratio-Topisone 0.05 % Lotion 0.21USD g Betamethasone va 0.1% cream 0.14USD g Betaderm Regular 0.1 % Ointment 0.1USD g Ratio-Ectosone Regular 0.1 % Cream 0.1USD g Valisone Scalp 0.1 % Lotion 0.1USD g Betaderm Regular 0.1 % Cream 0.09USD g Ratio-Ectosone Scalp 0.1 % Lotion 0.09USD g Betaderm Mild 0.05 % Ointment 0.07USD g Betaderm Mild 0.05 % Cream 0.06USD g Ratio-Ectosone Mild 0.05 % Cream 0.06USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6126920 No 2000-10-03 2016-03-01 US US7078058 No 2006-07-18 2017-05-24 US US6753013 No 2004-06-22 2020-01-27 US US6787529 No 2004-09-07 2020-01-27 US US9119781 Yes 2015-09-01 2031-12-10 US US9439911 No 2016-09-13 2030-08-31 US US9433630 No 2016-09-06 2030-08-31 US US9655907 No 2017-05-23 2030-08-31 US US9364485 No 2016-06-14 2030-08-31 US US9775851 No 2017-10-03 2030-08-31 US US9877974 No 2018-01-30 2030-08-31 US US10130640 Yes 2018-11-20 2031-12-10 US US10179137 No 2019-01-15 2030-08-31 US US9566286 No 2017-02-14 2031-06-10 US US10617698 No 2020-04-14 2031-06-10 US US10660908 No 2020-05-26 2031-06-10 US US10688108 No 2020-06-23 2031-06-10 US US10682364 No 2020-06-16 2031-06-10 US US10716799 No 2020-07-21 2031-06-10 US US10265265 No 2019-04-23 2027-09-27 US US11638711 No 2019-03-18 2039-03-18 US US11696919 No 2019-03-18 2039-03-18 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 178°C http://www.chemspider.com/Chemical-Structure.20490.html boiling point (°C) 568.2°C http://www.chemspider.com/Chemical-Structure.9399.html water solubility 66.5 mg/L (at 25 °C) EPA logP 1.138 http://www.chemspider.com/Chemical-Structure.9399.html logS -3.77 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.0505 mg/mL ALOGPS logP 1.93 ALOGPS logP 1.68 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 12.42 Chemaxon pKa (Strongest Basic) -3.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 94.83 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 102.49 m3·mol-1 Chemaxon Polarizability 40.81 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.992 Blood Brain Barrier + 0.9781 Caco-2 permeable + 0.8304 P-glycoprotein substrate Substrate 0.7862 P-glycoprotein inhibitor I Non-inhibitor 0.8112 P-glycoprotein inhibitor II Non-inhibitor 0.8134 Renal organic cation transporter Non-inhibitor 0.7971 CYP450 2C9 substrate Non-substrate 0.8733 CYP450 2D6 substrate Non-substrate 0.9115 CYP450 3A4 substrate Substrate 0.7315 CYP450 1A2 substrate Non-inhibitor 0.938 CYP450 2C9 inhibitor Non-inhibitor 0.9106 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9247 CYP450 3A4 inhibitor Non-inhibitor 0.8308 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9169 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.9399 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.1482 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9558 hERG inhibition (predictor II) Inhibitor 0.5091
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 197.6079403 predictedDarkChem Lite v0.1.0 [M-H]- 180.6232695 predictedDarkChem Lite v0.1.0 [M-H]- 193.71138 predictedDeepCCS 1.0 (2019) [M+H]+ 198.8185403 predictedDarkChem Lite v0.1.0 [M+H]+ 190.1206101 predictedDarkChem Lite v0.1.0 [M+H]+ 195.6068 predictedDeepCCS 1.0 (2019) [M+Na]+ 198.9098403 predictedDarkChem Lite v0.1.0 [M+Na]+ 203.3081891 predictedDarkChem Lite v0.1.0 [M+Na]+ 201.55612 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [Article]
- Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [Article]
- Johnstone JF, Bocking AD, Unlugedik E, Challis JR: The effects of chorioamnionitis and betamethasone on 11beta hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor in preterm human placenta. J Soc Gynecol Investig. 2005 May;12(4):238-45. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
- Gene Name
- CYP19A1
- Uniprot ID
- P11511
- Uniprot Name
- Aromatase
- Molecular Weight
- 57882.48 Da
References
- Paakki P, Kirkinen P, Helin H, Pelkonen O, Raunio H, Pasanen M: Antepartum glucocorticoid therapy suppresses human placental xenobiotic and steroid metabolizing enzymes. Placenta. 2000 Mar-Apr;21(2-3):241-6. doi: 10.1053/plac.1999.0471. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
- Matsunaga T, Maruyama M, Matsubara T, Nagata K, Yamazoe Y, Ohmori S: Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells. Drug Metab Pharmacokinet. 2012;27(6):653-7. doi: 10.2133/dmpk.dmpk-12-nt-018. Epub 2012 May 22. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Matsunaga T, Maruyama M, Matsubara T, Nagata K, Yamazoe Y, Ohmori S: Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells. Drug Metab Pharmacokinet. 2012;27(6):653-7. doi: 10.2133/dmpk.dmpk-12-nt-018. Epub 2012 May 22. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1B1
- Uniprot ID
- Q16678
- Uniprot Name
- Cytochrome P450 1B1
- Molecular Weight
- 60845.33 Da
References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Matsunaga T, Maruyama M, Matsubara T, Nagata K, Yamazoe Y, Ohmori S: Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells. Drug Metab Pharmacokinet. 2012;27(6):653-7. doi: 10.2133/dmpk.dmpk-12-nt-018. Epub 2012 May 22. [Article]
- Academic disertation [Link]
- Celestone monograph [File]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Pontremoli C, Barbero N, Viscardi G, Visentin S: Insight into the interaction of inhaled corticosteroids with human serum albumin: A spectroscopic-based study. J Pharm Anal. 2018 Feb;8(1):37-44. doi: 10.1016/j.jpha.2017.07.003. Epub 2017 Jul 5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid binding
- Specific Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Simard M, Underhill C, Hammond GL: Functional implications of corticosteroid-binding globulin N-glycosylation. J Mol Endocrinol. 2018 Feb;60(2):71-84. doi: 10.1530/JME-17-0234. Epub 2017 Dec 22. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55